Anish Kirpalani1,2, Eyesha Hashim3, General Leung3,2, Jin K Kim3, Adriana Krizova4, Serge Jothy4, Maya Deeb5, Nan N Jiang3, Lauren Glick6, Gevork Mnatzakanian3, Darren A Yuen5,6. 1. Departments of Medical Imaging and kirpalania@smh.ca. 2. Li Ka Shing Knowledge Institute and. 3. Departments of Medical Imaging and. 4. Laboratory Medicine and Pathology and. 5. Division of Nephrology, Department of Medicine, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada; and. 6. Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, Canada.
Abstract
BACKGROUND AND OBJECTIVES: Fibrosis is a major cause of kidney allograft injury. Currently, the only means of assessing allograft fibrosis is by biopsy, an invasive procedure that samples <1% of the kidney. We examined whether magnetic resonance elastography, an imaging-based measure of organ stiffness, could noninvasively estimate allograft fibrosis and predict progression of allograft dysfunction. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney allograft recipients >1 year post-transplant undergoing an allograft biopsy first underwent free-breathing, flow-compensated magnetic resonance elastography on a 3.0-T magnetic resonance imaging scanner. Each patient had serial eGFR measurements after the elastography scan for a follow-up period of up to 1 year. The mean stiffness value of the kidney allograft was compared with both the histopathologic Banff fibrosis score and the rate of eGFR change during the follow-up period. RESULTS: Sixteen patients who underwent magnetic resonance elastography and biopsy were studied (mean age: 54±9 years old). Whole-kidney mean stiffness ranged between 3.5 and 7.3 kPa. Whole-kidney stiffness correlated with biopsy-derived Banff fibrosis score (Spearman rho =0.67; P<0.01). Stiffness was heterogeneously distributed within each kidney, providing a possible explanation for the lack of a stronger stiffness-fibrosis correlation. We also found negative correlations between whole-kidney stiffness and both baseline eGFR (Spearman rho =-0.65; P<0.01) and eGFR change over time (Spearman rho =-0.70; P<0.01). Irrespective of the baseline eGFR, increased kidney stiffness was associated with a greater eGFR decline (regression r2=0.48; P=0.03). CONCLUSIONS: Given the limitations of allograft biopsy, our pilot study suggests the potential for magnetic resonance elastography as a novel noninvasive measure of whole-allograft fibrosis burden that may predict future changes in kidney function. Future studies exploring the utility and accuracy of magnetic resonance elastography are needed.
BACKGROUND AND OBJECTIVES:Fibrosis is a major cause of kidney allograft injury. Currently, the only means of assessing allograft fibrosis is by biopsy, an invasive procedure that samples <1% of the kidney. We examined whether magnetic resonance elastography, an imaging-based measure of organ stiffness, could noninvasively estimate allograft fibrosis and predict progression of allograft dysfunction. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney allograft recipients >1 year post-transplant undergoing an allograft biopsy first underwent free-breathing, flow-compensated magnetic resonance elastography on a 3.0-T magnetic resonance imaging scanner. Each patient had serial eGFR measurements after the elastography scan for a follow-up period of up to 1 year. The mean stiffness value of the kidney allograft was compared with both the histopathologic Banff fibrosis score and the rate of eGFR change during the follow-up period. RESULTS: Sixteen patients who underwent magnetic resonance elastography and biopsy were studied (mean age: 54±9 years old). Whole-kidney mean stiffness ranged between 3.5 and 7.3 kPa. Whole-kidney stiffness correlated with biopsy-derived Banff fibrosis score (Spearman rho =0.67; P<0.01). Stiffness was heterogeneously distributed within each kidney, providing a possible explanation for the lack of a stronger stiffness-fibrosis correlation. We also found negative correlations between whole-kidney stiffness and both baseline eGFR (Spearman rho =-0.65; P<0.01) and eGFR change over time (Spearman rho =-0.70; P<0.01). Irrespective of the baseline eGFR, increased kidney stiffness was associated with a greater eGFR decline (regression r2=0.48; P=0.03). CONCLUSIONS: Given the limitations of allograft biopsy, our pilot study suggests the potential for magnetic resonance elastography as a novel noninvasive measure of whole-allograft fibrosis burden that may predict future changes in kidney function. Future studies exploring the utility and accuracy of magnetic resonance elastography are needed.
Authors: Laurent Huwart; Christine Sempoux; Eric Vicaut; Najat Salameh; Laurence Annet; Etienne Danse; Frank Peeters; Leon C ter Beek; Jacques Rahier; Ralph Sinkus; Yves Horsmans; Bernard E Van Beers Journal: Gastroenterology Date: 2008-04-04 Impact factor: 22.682
Authors: M Naesens; D R J Kuypers; K De Vusser; Y Vanrenterghem; P Evenepoel; K Claes; B Bammens; B Meijers; E Lerut Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086
Authors: Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce Journal: Mol Cell Endocrinol Date: 2019-02-14 Impact factor: 4.102
Authors: Chanon Chantaduly; Hayden R Troutt; Karla A Perez Reyes; Jonathan E Zuckerman; Peter D Chang; Wei Ling Lau Journal: Kidney360 Date: 2021-11-11
Authors: Eno Hysi; Xiaolin He; Muhannad N Fadhel; Tianzhou Zhang; Adriana Krizova; Michael Ordon; Monica Farcas; Kenneth T Pace; Victoria Mintsopoulos; Warren L Lee; Michael C Kolios; Darren A Yuen Journal: JCI Insight Date: 2020-05-21